Cargando…
Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination
BACKGROUND: This placebo-controlled study assessed the effects of the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta(2)-agonist (LABA) vilanterol (VI) on early and late asthmatic responses (EAR/LAR) and airway hyper-responsiveness (AHR). METHODS: Patients (n =...
Autores principales: | Oliver, A, Bjermer, L, Quinn, D, Saggu, P, Thomas, P, Yarnall, K, Lötvall, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223930/ https://www.ncbi.nlm.nih.gov/pubmed/23924233 http://dx.doi.org/10.1111/all.12205 |
Ejemplares similares
-
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
por: O’Byrne, Paul M., et al.
Publicado: (2014) -
A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects
por: Kempsford, Rodger, et al.
Publicado: (2014) -
Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
por: Bateman, Eric D, et al.
Publicado: (2014) -
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020) -
Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial
por: Lötvall, J, et al.
Publicado: (2012)